Example: dental hygienist
New Zealand Datasheet - Medsafe
adalimumab administered fortnightly as a single dose via subcutaneous injection. Glucocorticoids, salicylates, nonsteroidal anti−inflammatory drugs, analgesics or disease-modifying anti-rheumatic drugs can be continued during treatment with Humira. Available data suggest that the clinical response is usually achieved within 12 weeks of treatment.
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
Related documents
MEDICATION GUIDE SIMPONI ARIA (golimumab) injection, for ...
www.janssenlabels.com• Your doctor should monitor you closely for signs and symptoms of TB during treatment with SIMPONI ARIA. ... HUMIRA (adalimumab), ENBREL (etanercept), or CIMZIA (certolizumab pegol). • receive RITUXAN (rituximab) or ACTEMRA (tocilizumab). ... blood counts before and during treatment with SIMPONI ARIA.
Welcome to HUMIRA Complete. - HUMIRA® (adalimumab)
www.humirapro.comHUMIRA, and check you closely for signs and symptoms of TB during treatment with HUMIRA, even if your TB test was negative. If your doctor feels you are at risk, you may be treated with medicine for TB. • Cancer. For children and adults taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase.
Inflammatory Bowel Disease
www.crohnscolitisfoundation.orgduring a bowel movement, usually within a day. ... signs and symptoms or is not responding to treatment, additional testing may be performed, such as blood tests, ... Biologic therapies, including infliximab, adalimumab, certolizumab pegol, golimumab, vedolizumab and natalizumab, areantibodies grown in the laboratory ...
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euincluding tuberculosis, before, during and after treatment with Humira. Because the elimination of adalimumab may take up to four months, monitoring should be continued throughout this period. Treatment with Humira should not be initiated in patients with active infections including chronic or localised infections untilinfections are controlled.
INTRODUCTION
s3-eu-west-1.amazonaws.comOthers can be more serious and will require treatment. Side effects of vedolizumab include the following: Immmediate reactions It is not common, but some symptoms may mean you are having a reaction to the infusion or an allergic reaction to vedolizumab. Tell your IBD team immediately if you notice any of the following symptoms during
ACG Clinical Guideline: Management of Crohn’s Disease in ...
acgcdn.gi.orgalleviating signs and symptoms in patients with steroid-dependent Crohn’s disease and for maintaining remission (conditional recommendation, low level of evidence). 24 Anti-TNF agents (infliximab, adalimumab, certolizumab pegol) should be used to treat Crohn’s